Results for the First Quarter 2023

NOK 82.1. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK, currency neutral decline of 3.7%. Currency neutral…

Read more

Presentation of Medistim’s Q1 2023 Financial Results

The financials will be presented via a live webinar on Tuesday, April 25th from 08:00-09:00 (CEST). Representatives for the company will be Kari Eian Krogstad (CEO), and Thomas Jakobsen (CFO). The recording will be made available on…

Read more

Annual Report 2022

Further supported by several high-quality symposia at the largest heart surgery conferences, we achieved 44 % growth in the imaging product portfolio in 2022. And while steadily penetrating the Cardiac bypass market, we also build…

Read more

Capital Markets Day

See the recording from Medistim's Capital Markets Day on March 21st where two international thought leaders, Professors John. D. Puskas and Pirkka Vikatmaa shared their insights on the future trends in Cardiac and Vascular Surgery…

Read more

Results for the third quarter 2022

In the third quarter, total revenue ended at MNOK 116.5 (MNOK 102.1), a 14.0% increase. Sales growth is driven by the USA with a currency-neutral sales increase of 18.7 % for the quarter and 24.1…

Read more